(MENAFN- GlobeNewsWire - Nasdaq) The biopharmaceuticals contract manufacturing market offers growth opportunities through increased demand for monoclonal antibodies, cell therapies, and biosimilars. Emerging markets like India and China are crucial due to cost advantages and evolving regulations. U.S. trade tariffs and technological advancements will shape global strategies.

Dublin, Oct. 15, 2025 (GLOBE NEWSWIRE) -- The "Biopharmaceuticals Contract Manufacturing Market Report 2025-2035" has been added to ResearchAndMarkets's offering.
World revenue for the Biopharmaceuticals Contract Manufacturing Market is set to surpass US$17 billion in 2025, with strong revenue growth through to 2035.
Biopharmaceutical contract manufacturing has become a critical enabler for companies navigating the complexity of biologics and advanced therapies. With rising demand for monoclonal antibodies, cell therapies, and gene therapies, outsourcing provides biopharma innovators with access to scalable, regulatory-compliant infrastructure while allowing them to concentrate resources on discovery and development. Contract manufacturing organisations (CMOs) play a pivotal role in reducing time-to-market, optimising costs, and offering technical expertise that many firms cannot replicate in-house.
The sector is experiencing strong growth, propelled by the expanding pipeline of therapies addressing oncology, rare diseases, and autoimmune conditions. Biosimilars are also a key driver, as patent expirations on blockbuster biologics fuel a wave of development and manufacturing partnerships. Both emerging biotech firms and global pharmaceutical leaders are increasingly turning to CMOs to achieve greater operational agility and capital efficiency. The COVID-19 pandemic further highlighted the importance of resilient, high-capacity networks, cementing CMOs as indispensable partners in global healthcare preparedness.
Technological advances, ranging from AI-driven process optimisation to continuous bioprocessing, are transforming efficiency and quality standards in outsourced production. At the same time, emerging markets such as India and China are becoming more integral to global supply chains, supported by cost competitiveness and improving regulatory frameworks. These dynamics are expanding the geographic footprint of contract manufacturing, diversifying risk, and opening new avenues for growth.
As demand for biologics and next-generation therapies accelerates, contract manufacturing will remain a cornerstone of the biopharmaceutical value chain. CMOs are evolving from capacity providers into strategic partners, offering innovation, resilience, and flexibility that are increasingly essential in a competitive and fast-changing global healthcare landscape.
Impact of US Trade Tariffs on the Global Biopharmaceuticals Contract Manufacturing Market
The introduction of U.S. trade tariffs on pharmaceutical inputs, biologics, and specialised manufacturing equipment is creating new pressures for the global biopharmaceutical contract manufacturing market. By raising the cost of raw materials, reagents, and critical production tools, these measures are disrupting established cost structures and supply chains. Contract manufacturers that rely on cross-border sourcing or export to the United States are particularly exposed, facing higher operating costs, potential delays, and reduced margins-factors that could translate into increased pricing for sponsors and limit the affordability of biologics and biosimilars.
At the same time, tariffs are prompting a reassessment of global outsourcing strategies. Biopharmaceutical companies are moving to diversify suppliers, invest in localised production capacity, and channel outsourcing toward regions unaffected by tariffs. This shift is increasing interest in Southeast Asia, India, and selected European markets, where improving regulatory standards and competitive cost bases support expansion. While U.S.-based CMOs may benefit in the short term from stronger domestic demand, their ability to maintain this position will depend on policy clarity and the scale of infrastructure investment.
In effect, tariffs are acting as both a disruptor and a catalyst-raising immediate costs while driving structural changes in how and where manufacturing is conducted. For CMOs and their partners, the priority will be to adapt quickly, balancing short-term challenges with the longer-term opportunity to build more resilient and regionally diversified supply networks.

Key Market Dynamics

• Market Driving Factors
  • Rise in Investment by CMOs for Capacity Expansion
  • Cost and Time Saving Benefits Offered by Contract Services
  • Outsourcing Boosting the Market Growth
  • Growing Investments in Orphan Drugs
• Market Restraining Factors
  • Pricing Pressure to Impede Market Growth
  • Stringent Regulatory Scenarios
  • Overcapacity Projected to Challenge Market Growth
• Market Opportunities
  • Expansion of Fill and Finish CMOs
  • Emergence of Single-Use Bioprocessing Equipment & Solutions
  • Emerging Economies to Offer Lucrative Growth Opportunities

Forecasts to 2035 and other analyses reveal commercial prospects

• In addition to revenue forecasting to 2035, the new study provides you with recent results, growth rates, and market shares.
• You will find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, and restraints), Porter's Five Forces Analysis, PEST Analysis and recent developments.

The report also includes profiles for some of the leading companies in the Biopharmaceuticals Contract Manufacturing Market, with a focus on this segment of these companies' operations.
Leading companies and the potential for market growth

• AbbVie Inc.
• AGC Biologics
• Avantor, Inc.
• Binex Co., Ltd.
• Boehringer Ingelheim International GmbH
• Cambrex Corporation
• Catalent, Inc
• Curia Global, Inc.
• Cytiva
• FUJIFILM Diosynth Biotechnologies
• JRS PHARMA
• Jubilant Pharma Limited
• KBI Biopharma
• Lonza
• Pfizer CentreOne
• ProBioGen AG
• Rentschler Biopharma SE
• Samsung Biologics
• Sandoz Group AG
• Toyobo Co., Ltd.
• Thermo Fisher Scientific Inc.
• WuXi Biologics

How will the Biopharmaceuticals Contract Manufacturing Market report help you?
In summary, the report provides you with the following knowledge:

• Revenue forecasts to 2035 for Biopharmaceuticals Contract Manufacturing Market 2025 to 2035, with forecasts for source, service, product, company size, and scale of operations, each forecast at a global and regional level - discover the industry's prospects, finding the most lucrative places for investments and revenues.
• Revenue forecasts to 2035 for five regional and 26 key national markets
• Prospects for established firms and those seeking to enter the market - including company profiles for 22 of the major companies involved in the Biopharmaceuticals Contract Manufacturing Market.

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: Laura Wood,Senior Press Manager ... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN15102025004107003653ID1110200737